Condition
Solid Malignancy
Total Trials
6
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Unknown2
Enrolling By Invitation1
Terminated1
Active Not Recruiting1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT01697930Phase 1Active Not RecruitingPrimary
A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)
NCT06208878Enrolling By Invitation
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
NCT06201663Phase 3Unknown
Romiplostim in Chemotherapy-Induced Thrombocytopenia
NCT03371420Early Phase 1Terminated
PET Imaging of Subjects Using 124I-PU-AD
NCT03299270Unknown
Geriatric Oncology Surgical Assessment and Functional rEcovery After Surgery
NCT02352844Phase 2CompletedPrimary
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Showing all 6 trials